Marinus Pharmaceuticals, Inc.
MRNSDelisted Feb 11, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001267813
Marinus Pharmaceuticals, Inc. was delisted on Feb 11, 2025; its insiders filed their last Form 4 on Feb 11, 2025; 53 institutions reported holding it in 13F filings for Q4 2024, worth $15.8M in total; no superinvestor held it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Marinus Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Marinus Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Manning Martha E | SVP, GEN. COUNSEL & CORP. SEC. | 0 | Feb 11, 2025 | 0 |
| Mayleben Timothy M | Director | 0 | Feb 11, 2025 | 0 |
| Ezickson Elan | Director | 0 | Feb 11, 2025 | 0 |
| Fischer Seth H. Z. | Director | 0 | Feb 11, 2025 | 0 |
| Braunstein Scott | CHAIRMAN AND CEO | 0 | Feb 11, 2025 | 0 |
| Silverstein Christine Berni | Director | 0 | Feb 11, 2025 | 0 |
| Hulihan Joseph | CHIEF MEDICAL OFFICER | 0 | Feb 11, 2025 | 0 |
| Johnson Marvin | Director | 0 | Feb 11, 2025 | 0 |
| Pfanstiel Steven | CFO AND COO | 0 | Feb 11, 2025 | 0 |
| Shafer Christina | CHIEF COMMERCIAL OFFICER | 0 | Feb 11, 2025 | 0 |
| Noonberg Sarah B. | Director | 14,100 | Jun 20, 2024 | 0 |
| Austin Charles | Director | 12,177 | Jun 20, 2024 | 0 |
| Nochur Sara | Director | 13,250 | Jun 20, 2024 | 0 |
| Dougherty Michael R | Director | 3,312 | Feb 7, 2022 | 0 |
| Vitullo Nicole | Director | 6,442 | Feb 7, 2022 | 0 |
| Arroyo Santiago | Director | 2,750 | Feb 7, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 11, 2025 (view filing) | Aug 14, 2024 | 181 daysLate | Braunstein ScottCHAIRMAN AND CEO | PPurchase | +5.93K | $1.10 | +$6.53K | +2.0%304.6K after | |
| Jan 23, 2025 (view filing) | Jan 21 | 2 days | Ezickson ElanDirector | SSale | −1.60K | $0.54 | −$864 | −12.8%10.9K after | 10b5-1 |
| Jan 23, 2025 (view filing) | Jan 21 | 2 days | Johnson MarvinDirector | SSale | −1.61K | $0.54 | −$869.4 | −11.4%12.5K after | 10b5-1 |
| Aug 7, 2024 (view filing) | Aug 5 | 2 days | Shafer ChristinaCHIEF COMMERCIAL OFFICER | SSale | −3.82K | $1.14 | −$4.35K | −5.4%67.4K after | |
| Aug 7, 2024 (view filing) | Aug 5 | 2 days | Pfanstiel StevenCFO AND COO | SSale | −4.66K | $1.13 | −$5.26K | −5.5%79.8K after | |
| Aug 7, 2024 (view filing) | Aug 5 | 2 days | Manning Martha ESVP, GEN. COUNSEL & CORP. SEC. | SSale | −3.62K | $1.13 | −$4.09K | −5.7%60.3K after | |
| Aug 7, 2024 (view filing) | Aug 5 | 2 days | Hulihan JosephCHIEF MEDICAL OFFICER | SSale | −4.83K | $1.13 | −$5.46K | −6.2%72.7K after | |
| Aug 7, 2024 (view filing) | Aug 5 | 2 days | Braunstein ScottCHAIRMAN AND CEO | SSale | −12.1K | $1.13 | −$13.7K | −3.9%298.7K after | |
| Feb 22, 2024 (view filing) | Feb 20 | 2 days | Shafer ChristinaCHIEF COMMERCIAL OFFICER | SSale | −2.15K | $9.56 | −$20.6K | −3.4%60.3K after | |
| Feb 22, 2024 (view filing) | Feb 20 | 2 days | Manning Martha ESVP, GEN. COUNSEL & CORP. SEC. | SSale | −1.89K | $9.57 | −$18.1K | −3.5%53.0K after | |
| Feb 21, 2024 (view filing) | Feb 16 | 5 days | Hulihan JosephCHIEF MEDICAL OFFICER | SSale | −2.81K | $9.98 | −$28.1K | −4.1%66.6K after | |
| Feb 21, 2024 (view filing) | Feb 16 | 5 days | Pfanstiel StevenCFO AND COO | SSale | −3.09K | $9.97 | −$30.8K | −4.1%71.7K after | |
| Feb 21, 2024 (view filing) | Feb 16 | 5 days | Braunstein ScottCHAIRMAN AND CEO | SSale | −11.8K | $9.94 | −$117.8K | −5.0%223.5K after | |
| Aug 8, 2023 (view filing) | Aug 7-8 | 1 day | Shafer ChristinaCHIEF COMMERCIAL OFFICER | SSale | −2.40K | $9.52 | −$22.8K | −5.6%40.6K after | 2 lots10b5-1 |
| Aug 8, 2023 (view filing) | Aug 7-8 | 1 day | Braunstein ScottCHAIRMAN AND CEO | SSale | −6.44K | $9.55 | −$61.5K | −3.9%160.8K after | 2 lots10b5-1 |
| Aug 8, 2023 (view filing) | Aug 7-8 | 1 day | Pfanstiel StevenCFO AND COO | SSale | −2.80K | $9.54 | −$26.7K | −5.4%49.3K after | 2 lots10b5-1 |
| Aug 8, 2023 (view filing) | Aug 7-8 | 1 day | Manning Martha ESVP, GEN. COUNSEL & CORP. SEC. | SSale | −2.18K | $9.54 | −$20.8K | −6.2%33.0K after | 2 lots10b5-1 |
| Aug 8, 2023 (view filing) | Aug 7-8 | 1 day | Hulihan JosephCHIEF MEDICAL OFFICER | SSale | −2.90K | $9.55 | −$27.7K | −5.7%47.6K after | 2 lots10b5-1 |
| Feb 8, 2023 (view filing) | Feb 6 | 2 days | Fischer Seth H. Z.Director | SSale | −1.02K | $6.54 | −$6.66K | −14.5%6.03K after | |
| Feb 8, 2023 (view filing) | Feb 6 | 2 days | Ezickson ElanDirector | SSale | −750 | $6.56 | −$4.92K | −11.8%5.60K after | |
| Feb 8, 2023 (view filing) | Feb 6 | 2 days | Austin CharlesDirector | SSale | −1.07K | $6.49 | −$6.96K | −16.9%5.28K after |